ClinicalTrials.gg
CompletedNCT05526430Updated Jan 16, 2025Results posted

Study of Harmine in Healthy Subjects

A Phase 1 interventional study of Harmine Hydrochloride Capsules in Diabetes Mellitus, sponsored by James Murrough. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by James Murrough · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,023 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 388 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Enrollment
1,897th of 2,502
27 · median 82
Started
2022
with 91 others
Phase 1
204 of 3,023
13 open now
Registered
2,640th of 3,023
by date

Among the 3,023 studies in Diabetes Mellitus with a site in United States, this one is the 1,897th largest by enrollment of the 2,502 interventional ones that give a count, is one of 92 that started in 2022, is one of 204 in phase 1, and was the 2,640th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

289 of the 3,023 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

284 more — sign in →

All 289 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,023 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

The present study is a phase 1 dose escalation study of harmine in healthy volunteers. The primary goal of the trial is to determine the maximum tolerated dose of harmine.

Read the detailed description

The present study is a phase 1 dose escalation study of harmine in healthy volunteers. The primary goal of the trial is to determine the maximum tolerated dose of harmine. Harmine will be administered in an open-label, dose escalation design that will use the continual reassessment method to inform the next dose to test in a subject. There will be a total of seven possible doses that include 100 mg, 200 mg, 300 mg, 500 mg, 700 mg, 900 mg and 1200 mg. Each study subject will receive a single oral dose of harmine in this single ascending dose design. On the treatment day, subjects will undergo continuous medical monitoring. All adverse events will be documented and events that qualify as dose limiting toxicities (DLTs) will be used to inform dosing for the subsequent subjects.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18-55 years;
  • Participants must have a level of understanding of the English language sufficient to agree to all tests and examinations required by the study and must be able to participate fully in the process;
  • (BMI) between 19 and 30;
  • Women of and men must be using an acceptable method of to avoid pregnancy throughout the study as judged by the investigator;
  • Women must not be breastfeeding;

Exclusion criteria

Exclusion Criteria

  • Children under the age of 18 and adults over the age of 55 due to concerns regarding neurodevelopmental and neurocognitive effects, respectively.
  • Individuals who are underweight as defined as a \<19, or who are obese as defined as >30 according to the Centers for Disease Control (CDC). These criteria are in line with the goals of a phase I dose finding and pharmacokinetic study.
  • Presence of a significant medical illness i.e., delirium, cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry;
  • Presence of a significant neurological disease such as Parkinson's disease, primary or secondary seizure disorders, intracranial tumors, severe head trauma; neurodegenerative diseases;
  • Presence of neurocognitive or dementing disorders;
  • Presence or history of psychiatric disorder as diagnosed by Mini Neuropsychiatric Interview (MINI);
  • Urine toxicology positive for illicit drugs or dis-allowed concomitant medications as per study protocol;
  • Medications with primary central nervous system (CNS) effects are dis-allowed, including psychotropic medications, antidepressants, benzodiazepines, centrally acting hypnotic agents, and centrally acting anti-migraine therapies;
  • Medications with primary cardiovascular effects are dis-allowed, including beta-adrenergic antagonists, ACE inhibitors, calcium channel blockers, and diuretics;
  • Any OTC medications or herbal remedies (see concomitant medications listed above) that could interfere with the study drug, pose a risk to the subject, or contain high tyramine as outlined in the Low Tyramine Diet attachment and above in the concomitant medication summary;
  • Any other medications that, in the opinion of the investigators, would pose a safety risk to the patient or that would interfere with the interpretation of study results; Positive pregnancy test at screen or on the morning of the treatment day in women of ;
  • Systolic blood pressure outside the range of 100 - 140 mmHg, diastolic blood pressure outside the range of 60 - 90 mmHg, and pulse rate at rest > 100 or \< 60 bpm;
  • History of positive tests for surface antigen, antibodies;
  • History of ;
  • Significant abnormalities as follows:
  • Heart Rate \< 60 and >100 bpm
  • PR Interval \<120 and > 220 ms
  • QRS duration \< 70 and >120 ms
  • (Bazett) > 450 ms
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Harmine Dose

    There will be a total of seven possible doses that include 100 mg, 200 mg, 300 mg, 500 mg, 700 mg, 900 mg and 1200 mg. Each study subject will receive a single oral dose of harmine in this single ascending dose design.

    Drug: Harmine Hydrochloride Capsules

Interventions

  • DrugHarmine Hydrochloride Capsules

    capsules taken orally

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicity (DLT)

    DLT which is defined if have any one of the following: Patient Rated Inventory of Side Effects (PRISE): 0-51, higher scores indicate more adverse events observed Brief Psychiatric Rating Scale (BPRS): 4 - 28, higher scores indicate more symptoms of psychosis Vitals: blood pressure and heart rate will all be measured - anything outside of the following ranges will be noted: * Symptomatic hypotension, or \> 20% decrease in systolic blood pressure (SBP) from pre-dosing and an absolute SBP \< 90; or * Symptomatic hypertension, or \> 20% increase in SBP or diastolic blood pressure (DBP) from predosing and absolute SBP \> 170 or DBP \> 95; * New onset tachycardia (heart rate \>100 bpm) and \>20% increase from pre-dosing; or symptomatic bradycardia (heart rate \<60 bpm) and \> 20% decrease from pre-dosing. * Signs and symptoms of cardiac ischemia, defined by acute ischemic changes on ECG with or without concomitant symptoms

    Time frame: 24 hours

  2. Maximum Tolerated Dose (MTD) of Oral Harmine HCl Based on Dose Limiting Toxicity (DLT)

    The MTD was determined to be between 100 and 200mg and is weight-based.

    Time frame: 24 hours

Secondary outcomes

  1. Visual Analog Scale (VAS) - Nausea

    Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly

    Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours

  2. Visual Analog Scale (VAS) - Hunger

    Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.

    Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours

  3. Visual Analog Scale (VAS) - Feeling High/Intoxicated

    Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly

    Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours

  4. Visual Analog Scale (VAS) - Drowsiness

    Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly

    Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours

  5. Visual Analog Scale (VAS) - Anxiety

    Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly

    Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours

  6. Visual Analog Scale (VAS) - Depressed Mood

    Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.

    Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours

  7. Visual Analog Scale (VAS) - Happy Mood

    Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly

    Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours

  8. Visual Analog Scale (VAS) - Excitement

    Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.

    Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours

  9. Visual Analog Scale (VAS) - Feeling of Control

    Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.

    Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours

  10. Visual Analog Scale (VAS) - Vividness of Image

    Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.

    Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours

  11. Profile of Mood States Bipolar Scale (POMS-Bi): Composed-Anxious Scale

    The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood

    Time frame: Baseline, 2, 6, 7, 8, and 24 hours

  12. Profile of Mood States Bipolar Scale (POMS-Bi): Agreeable-Hostile Scale

    The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood

    Time frame: Baseline, 2, 6, 7, 8, and 24 hours

  13. Profile of Mood States Bipolar Scale (POMS-Bi): Elated-Depression Scale

    The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood

    Time frame: Baseline, 2, 6, 7, 8, and 24 hours

  14. Profile of Mood States Bipolar Scale (POMS-Bi): Confident-Unsure Scale

    The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood

    Time frame: Baseline, 2, 6, 7, 8, and 24 hours

  15. Profile of Mood States Bipolar Scale (POMS-Bi): Energetic-Tired Scale

    The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood

    Time frame: Baseline, 2, 6, 7, 8, and 24 hours

  16. Profile of Mood States Bipolar Scale (POMS-Bi): Clearheaded-Confused Scale

    The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood

    Time frame: Baseline, 2, 6, 7, 8, and 24 hours

  17. Perceived Stress Scale (PSS)

    The PSS is a 10-item self-report scale that measures the perception of stress. Each item is rated on a scale from 0-4. Full scale from 0-40, with higher score indicating more perceived stress

    Time frame: 24 hours

  18. Patient Rated Inventory of Side Effects (PRISE)

    The PRISE is a self-report Adverse Event (AE) Checklist used to qualify side effects by identifying and evaluating the tolerability of each symptom. Only new onset or worsening symptoms were included. Participants could report more than one AE.

    Time frame: 24 hours

  19. Brief Psychiatric Rating Scale (BPRS)

    The BPRS is a 16-item clinician- administered scale that captures acute behavioral changes throughout treatment. Each item is rated on a scale from 1-7. Full scale from 16-112 with higher score indicating more worse health outcomes.

    Time frame: Baseline, 2, 6, 7, 8, and 24 hours

  20. Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a clinician-administered suicidal ideation and behavior rating scale used to evaluate suicide risk. Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation).

    Time frame: 24 hours

07

Results

Posted Jan 16, 2025

Participant flow

Between September 2022, and June 2023, a total of 34 participants signed consent with 7 failed screening. 27 were enrolled

Participant flow — Overall Study
MilestoneHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride 300mgHarmine Hydrochloride 500mg
Started101241
Completed101041
Not completed0200
Withdrew: Withdrawal by subject0200

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicity (DLT)

DLT which is defined if have any one of the following: Patient Rated Inventory of Side Effects (PRISE): 0-51, higher scores indicate more adverse events observed Brief Psychiatric Rating Scale (BPRS): 4 - 28, higher scores indicate more symptoms of psychosis Vitals: blood pressure and heart rate will all be measured - anything outside of the following ranges will be noted: * Symptomatic hypotension, or \> 20% decrease in systolic blood pressure (SBP) from pre-dosing and an absolute SBP \< 90; or * Symptomatic hypertension, or \> 20% increase in SBP or diastolic blood pressure (DBP) from predosing and absolute SBP \> 170 or DBP \> 95; * New onset tachycardia (heart rate \>100 bpm) and \>20% increase from pre-dosing; or symptomatic bradycardia (heart rate \<60 bpm) and \> 20% decrease from pre-dosing. * Signs and symptoms of cardiac ischemia, defined by acute ischemic changes on ECG with or without concomitant symptoms

Time frame:
24 hours
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicity (DLT)
ParticipantsHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride 300mgHarmine Hydrochloride 500mg
Number of Participants With Dose Limiting Toxicity (DLT)0641
PrimaryMaximum Tolerated Dose (MTD) of Oral Harmine HCl Based on Dose Limiting Toxicity (DLT)

The MTD was determined to be between 100 and 200mg and is weight-based.

Time frame:
24 hours
Reported as:
Number · mg/kg
Maximum Tolerated Dose (MTD) of Oral Harmine HCl Based on Dose Limiting Toxicity (DLT)
mg/kgHarmine Hydrochloride
Maximum Tolerated Dose (MTD) of Oral Harmine HCl Based on Dose Limiting Toxicity (DLT)2.7
SecondaryVisual Analog Scale (VAS) - Nausea

Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly

Time frame:
baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS) - Nausea
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
baseline0.13 (0 to 10)0.33 (0 to 10)0.10 (0 to 10)
0.5 hours0.71 (0 to 10)0.80 (0 to 10)0.12 (0 to 10)
1 hour0.39 (0 to 10)2.40 (0 to 10)2.30 (0 to 10)
1.5 hours0.44 (0 to 10)2.25 (0 to 10)2.82 (0 to 10)
2 hours0.69 (0 to 10)1.78 (0 to 10)2.22 (0 to 10)
3 hours0.25 (0 to 10)0.93 (0 to 10)1.04 (0 to 10)
4 hours0.37 (0 to 10)0.48 (0 to 10)0.94 (0 to 10)
5 hours0.23 (0 to 10)0.46 (0 to 10)0.60 (0 to 10)
6 hours0.24 (0 to 10)0.29 (0 to 10)0.16 (0 to 10)
7 hours0.28 (0 to 10)0.65 (0 to 10)0.14 (0 to 10)
8 hours0.23 (0 to 10)0.39 (0 to 10)0.16 (0 to 10)
24 hours0.25 (0 to 10)0.32 (0 to 10)0.08 (0 to 10)
SecondaryVisual Analog Scale (VAS) - Hunger

Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.

Time frame:
baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS) - Hunger
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
baseline2.31 (0 to 10)3.91 (0 to 10)2.96 (0 to 10)
0.5 hours4.10 (0 to 10)3.40 (0 to 10)4.32 (0 to 10)
1 hour2.64 (0 to 10)3.58 (0 to 10)4.66 (0 to 10)
1.5 hours5.39 (0 to 10)4.26 (0 to 10)5.88 (0 to 10)
2 hours5.38 (0 to 10)4.74 (0 to 10)4.94 (0 to 10)
3 hours4.68 (0 to 10)4.65 (0 to 10)5.36 (0 to 10)
4 hours4.14 (0 to 10)4.78 (0 to 10)6.16 (0 to 10)
5 hours2.56 (0 to 10)1.85 (0 to 10)2.54 (0 to 10)
6 hours2.98 (0 to 10)2.02 (0 to 10)3.86 (0 to 10)
7 hours3.66 (0 to 10)3.35 (0 to 10)4.02 (0 to 10)
8 hours2.87 (0 to 10)4.29 (0 to 10)4.30 (0 to 10)
24 hours3.95 (0 to 10)3.51 (0 to 10)4.74 (0 to 10)
SecondaryVisual Analog Scale (VAS) - Feeling High/Intoxicated

Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly

Time frame:
baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS) - Feeling High/Intoxicated
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
baseline0.80 (0 to 10)0.44 (0 to 10)0.12 (0 to 10)
0.5 hours0.77 (0 to 10)0.88 (0 to 10)3.52 (0 to 10)
1 hour1.09 (0 to 10)2.23 (0 to 10)4.52 (0 to 10)
1.5 hours1.29 (0 to 10)2.43 (0 to 10)3.1 (0 to 10)
2 hours0.18 (0 to 10)2.27 (0 to 10)2.74 (0 to 10)
3 hours0.54 (0 to 10)0.62 (0 to 10)0.16 (0 to 10)
4 hours0.84 (0 to 10)0.57 (0 to 10)0.22 (0 to 10)
5 hours0.40 (0 to 10)0.49 (0 to 10)0.22 (0 to 10)
6 hours0.53 (0 to 10)0.66 (0 to 10)0.18 (0 to 10)
7 hours0.76 (0 to 10)0.65 (0 to 10)0.12 (0 to 10)
8 hours0.56 (0 to 10)0.86 (0 to 10)0.14 (0 to 10)
24 hours0.62 (0 to 10)0.54 (0 to 10)0.12 (0 to 10)
SecondaryVisual Analog Scale (VAS) - Drowsiness

Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly

Time frame:
baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS) - Drowsiness
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
baseline1.43 (0 to 10)2.14 (0 to 10)2.46 (0 to 10)
0.5 hours1.98 (0 to 10)3.04 (0 to 10)3.10 (0 to 10)
1 hour2.54 (0 to 10)3.02 (0 to 10)3.60 (0 to 10)
1.5 hours2.58 (0 to 10)3.96 (0 to 10)4.50 (0 to 10)
2 hours1.97 (0 to 10)3.86 (0 to 10)4.72 (0 to 10)
3 hours1.58 (0 to 10)3.24 (0 to 10)3.46 (0 to 10)
4 hours2.29 (0 to 10)2.56 (0 to 10)3.32 (0 to 10)
5 hours1.10 (0 to 10)1.86 (0 to 10)2.50 (0 to 10)
6 hours1.86 (0 to 10)1.73 (0 to 10)0.96 (0 to 10)
7 hours1.75 (0 to 10)1.77 (0 to 10)2.92 (0 to 10)
8 hours1.43 (0 to 10)2.20 (0 to 10)2.20 (0 to 10)
24 hours1.80 (0 to 10)1.00 (0 to 10)2.68 (0 to 10)
SecondaryVisual Analog Scale (VAS) - Anxiety

Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly

Time frame:
baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS) - Anxiety
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
baseline0.38 (0 to 10)1.01 (0 to 10)0.42 (0 to 10)
0.5 hours0.33 (0 to 10)0.79 (0 to 10)2.58 (0 to 10)
1 hour1 (0 to 10)1.03 (0 to 10)1.56 (0 to 10)
1.5 hours0.59 (0 to 10)0.76 (0 to 10)0.70 (0 to 10)
2 hours0.53 (0 to 10)0.78 (0 to 10)0.22 (0 to 10)
3 hours0.42 (0 to 10)0.54 (0 to 10)0.08 (0 to 10)
4 hours0.38 (0 to 10)0.55 (0 to 10)0.28 (0 to 10)
5 hours0.24 (0 to 10)0.58 (0 to 10)0.26 (0 to 10)
6 hours0.28 (0 to 10)0.51 (0 to 10)0.20 (0 to 10)
7 hours0.19 (0 to 10)0.53 (0 to 10)0.04 (0 to 10)
8 hours0.17 (0 to 10)0.62 (0 to 10)0.12 (0 to 10)
24 hours0.31 (0 to 10)0.57 (0 to 10)0.14 (0 to 10)
SecondaryVisual Analog Scale (VAS) - Depressed Mood

Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.

Time frame:
baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS) - Depressed Mood
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
baseline0.19 (0 to 10)0.33 (0 to 10)0.38 (0 to 10)
0.5 hours1.18 (0 to 10)0.41 (0 to 10)0.16 (0 to 10)
1 hour0.26 (0 to 10)0.28 (0 to 10)0.46 (0 to 10)
1.5 hours0.28 (0 to 10)0.44 (0 to 10)0.24 (0 to 10)
2 hours0.64 (0 to 10)0.38 (0 to 10)0.10 (0 to 10)
3 hours0.22 (0 to 10)0.36 (0 to 10)0.14 (0 to 10)
4 hours0.24 (0 to 10)0.38 (0 to 10)0.28 (0 to 10)
5 hours0.22 (0 to 10)0.28 (0 to 10)0.84 (0 to 10)
6 hours0.20 (0 to 10)0.18 (0 to 10)0.16 (0 to 10)
7 hours0.31 (0 to 10)0.29 (0 to 10)0.12 (0 to 10)
8 hours0.20 (0 to 10)0.31 (0 to 10)0.16 (0 to 10)
24 hours0.20 (0 to 10)0.33 (0 to 10)0.12 (0 to 10)
SecondaryVisual Analog Scale (VAS) - Happy Mood

Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly

Time frame:
baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS) - Happy Mood
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
baseline6.13 (0 to 10)5.22 (0 to 10)5.60 (0 to 10)
0.5 hours5.73 (0 to 10)4.28 (0 to 10)5.50 (0 to 10)
1 hour5.63 (0 to 10)4.27 (0 to 10)4.80 (0 to 10)
1.5 hours4.90 (0 to 10)4.45 (0 to 10)3.94 (0 to 10)
2 hours5.34 (0 to 10)3.83 (0 to 10)3.72 (0 to 10)
3 hours5.43 (0 to 10)3.98 (0 to 10)4.12 (0 to 10)
4 hours5.70 (0 to 10)4.50 (0 to 10)5.22 (0 to 10)
5 hours5.10 (0 to 10)4.34 (0 to 10)4.20 (0 to 10)
6 hours5.07 (0 to 10)4.39 (0 to 10)5.02 (0 to 10)
7 hours5.37 (0 to 10)4.17 (0 to 10)4.32 (0 to 10)
8 hours5.70 (0 to 10)4.19 (0 to 10)4.36 (0 to 10)
24 hours5.84 (0 to 10)4.85 (0 to 10)4.84 (0 to 10)
SecondaryVisual Analog Scale (VAS) - Excitement

Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.

Time frame:
baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS) - Excitement
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
baseline2.55 (0 to 10)2.12 (0 to 10)3.90 (0 to 10)
0.5 hours2.35 (0 to 10)1.44 (0 to 10)3.92 (0 to 10)
1 hour2.66 (0 to 10)2.10 (0 to 10)3.46 (0 to 10)
1.5 hours1.53 (0 to 10)1.89 (0 to 10)2.48 (0 to 10)
2 hours2.37 (0 to 10)2.02 (0 to 10)2.92 (0 to 10)
3 hours2.50 (0 to 10)1.65 (0 to 10)3.16 (0 to 10)
4 hours2.49 (0 to 10)2.29 (0 to 10)2.76 (0 to 10)
5 hours2.25 (0 to 10)2.17 (0 to 10)2.16 (0 to 10)
6 hours3.21 (0 to 10)1.42 (0 to 10)2.36 (0 to 10)
7 hours2.54 (0 to 10)1.02 (0 to 10)2.68 (0 to 10)
8 hours2.58 (0 to 10)1.39 (0 to 10)2.70 (0 to 10)
24 hours4.01 (0 to 10)2.35 (0 to 10)2.98 (0 to 10)
SecondaryVisual Analog Scale (VAS) - Feeling of Control

Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.

Time frame:
baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS) - Feeling of Control
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
baseline4.00 (0 to 10)3.27 (0 to 10)3.24 (0 to 10)
0.5 hours3.84 (0 to 10)2.00 (0 to 10)5.46 (0 to 10)
1 hour3.14 (0 to 10)3.81 (0 to 10)3.96 (0 to 10)
1.5 hours3.39 (0 to 10)1.91 (0 to 10)4.04 (0 to 10)
2 hours3.48 (0 to 10)3.07 (0 to 10)4.24 (0 to 10)
3 hours4.13 (0 to 10)2.17 (0 to 10)3.56 (0 to 10)
4 hours4.22 (0 to 10)2.87 (0 to 10)3.56 (0 to 10)
5 hours3.07 (0 to 10)2.51 (0 to 10)3.48 (0 to 10)
6 hours3.75 (0 to 10)2.14 (0 to 10)4.44 (0 to 10)
7 hours3.76 (0 to 10)1.80 (0 to 10)4.50 (0 to 10)
8 hours3.83 (0 to 10)2.11 (0 to 10)4.56 (0 to 10)
24 hours3.94 (0 to 10)3.52 (0 to 10)5.30 (0 to 10)
SecondaryVisual Analog Scale (VAS) - Vividness of Image

Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.

Time frame:
baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS) - Vividness of Image
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
baseline5.34 (0 to 10)2.99 (0 to 10)2.10 (0 to 10)
0.5 hours5.03 (0 to 10)2.42 (0 to 10)3.50 (0 to 10)
1 hour5.17 (0 to 10)2.94 (0 to 10)4.24 (0 to 10)
1.5 hours5.21 (0 to 10)2.75 (0 to 10)3.76 (0 to 10)
2 hours5.33 (0 to 10)2.57 (0 to 10)3.24 (0 to 10)
3 hours5.82 (0 to 10)2.76 (0 to 10)2.04 (0 to 10)
4 hours5.70 (0 to 10)2.61 (0 to 10)2.32 (0 to 10)
5 hours5.78 (0 to 10)2.45 (0 to 10)2.02 (0 to 10)
6 hours5.72 (0 to 10)2.21 (0 to 10)2.58 (0 to 10)
7 hours5.70 (0 to 10)2.17 (0 to 10)2.16 (0 to 10)
8 hours5.94 (0 to 10)2.39 (0 to 10)2.50 (0 to 10)
24 hours5.91 (0 to 10)2.45 (0 to 10)2.20 (0 to 10)
SecondaryProfile of Mood States Bipolar Scale (POMS-Bi): Composed-Anxious Scale

The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood

Time frame:
Baseline, 2, 6, 7, 8, and 24 hours
Reported as:
Mean · score on a scale
Profile of Mood States Bipolar Scale (POMS-Bi): Composed-Anxious Scale
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
Baseline33.9 (0 to 36)29.3 (0 to 36)33.6 (0 to 36)
2 hours31.7 (0 to 36)28.5 (0 to 36)29 (0 to 36)
6 hours31.9 (0 to 36)30.7 (0 to 36)33.6 (0 to 36)
7 hours33.5 (0 to 36)29.1 (0 to 36)32.8 (0 to 36)
8 hours32.7 (0 to 36)29.2 (0 to 36)31.4 (0 to 36)
24 hours33.1 (0 to 36)29.3 (0 to 36)33.0 (0 to 36)
SecondaryProfile of Mood States Bipolar Scale (POMS-Bi): Agreeable-Hostile Scale

The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood

Time frame:
Baseline, 2, 6, 7, 8, and 24 hours
Reported as:
Mean · score on a scale
Profile of Mood States Bipolar Scale (POMS-Bi): Agreeable-Hostile Scale
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
Baseline31.5 (0 to 36)28.7 (0 to 36)31.6 (0 to 36)
2 hours30.0 (0 to 36)28.1 (0 to 36)29.2 (0 to 36)
6 hours31.1 (0 to 36)28.1 (0 to 36)30.6 (0 to 36)
7 hours31.8 (0 to 36)27.0 (0 to 36)30.6 (0 to 36)
8 hours32.2 (0 to 36)27.7 (0 to 36)30.0 (0 to 36)
24 hours33.0 (0 to 36)27.6 (0 to 36)29.8 (0 to 36)
SecondaryProfile of Mood States Bipolar Scale (POMS-Bi): Elated-Depression Scale

The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood

Time frame:
Baseline, 2, 6, 7, 8, and 24 hours
Reported as:
Mean · score on a scale
Profile of Mood States Bipolar Scale (POMS-Bi): Elated-Depression Scale
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
Baseline29.1 (0 to 36)25.6 (0 to 36)27.0 (0 to 36)
2 hours28.1 (0 to 36)24.6 (0 to 36)24.6 (0 to 36)
6 hours29.0 (0 to 36)25.8 (0 to 36)27.2 (0 to 36)
7 hours28.9 (0 to 36)24.7 (0 to 36)25.6 (0 to 36)
8 hours29.8 (0 to 36)25.0 (0 to 36)26.0 (0 to 36)
24 hours31.4 (0 to 36)25.5 (0 to 36)26.0 (0 to 36)
SecondaryProfile of Mood States Bipolar Scale (POMS-Bi): Confident-Unsure Scale

The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood

Time frame:
Baseline, 2, 6, 7, 8, and 24 hours
Reported as:
Mean · score on a scale
Profile of Mood States Bipolar Scale (POMS-Bi): Confident-Unsure Scale
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
Baseline27.4 (0 to 36)24.3 (0 to 36)27.4 (0 to 36)
2 hours24.8 (0 to 36)22.6 (0 to 36)21.6 (0 to 36)
6 hours26.5 (0 to 36)24.5 (0 to 36)22.4 (0 to 36)
7 hours27.1 (0 to 36)22.9 (0 to 36)23.4 (0 to 36)
8 hours27.0 (0 to 36)23.2 (0 to 36)24 (0 to 36)
24 hours29.0 (0 to 36)24.6 (0 to 36)26.0 (0 to 36)
SecondaryProfile of Mood States Bipolar Scale (POMS-Bi): Energetic-Tired Scale

The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood

Time frame:
Baseline, 2, 6, 7, 8, and 24 hours
Reported as:
Mean · score on a scale
Profile of Mood States Bipolar Scale (POMS-Bi): Energetic-Tired Scale
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
Baseline24.5 (0 to 36)20.9 (0 to 36)21.8 (0 to 36)
2 hours22.0 (0 to 36)14.5 (0 to 36)7.2 (0 to 36)
6 hours23.1 (0 to 36)20.1 (0 to 36)19.6 (0 to 36)
7 hours23.5 (0 to 36)20.2 (0 to 36)16.2 (0 to 36)
8 hours26.1 (0 to 36)20.5 (0 to 36)19.4 (0 to 36)
24 hours29.3 (0 to 36)24.0 (0 to 36)20.8 (0 to 36)
SecondaryProfile of Mood States Bipolar Scale (POMS-Bi): Clearheaded-Confused Scale

The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood

Time frame:
Baseline, 2, 6, 7, 8, and 24 hours
Reported as:
Mean · score on a scale
Profile of Mood States Bipolar Scale (POMS-Bi): Clearheaded-Confused Scale
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
Baseline31.1 (0 to 36)27.9 (0 to 36)31.2 (0 to 36)
2 hours29.0 (0 to 36)24.7 (0 to 36)22.2 (0 to 36)
6 hours30.3 (0 to 36)27.5 (0 to 36)29.6 (0 to 36)
7 hours30.6 (0 to 36)26.9 (0 to 36)27.8 (0 to 36)
8 hours31.2 (0 to 36)26.6 (0 to 36)28.6 (0 to 36)
24 hours32.4 (0 to 36)28.3 (0 to 36)30.0 (0 to 36)
SecondaryPerceived Stress Scale (PSS)

The PSS is a 10-item self-report scale that measures the perception of stress. Each item is rated on a scale from 0-4. Full scale from 0-40, with higher score indicating more perceived stress

Time frame:
24 hours
Reported as:
Mean · score on a scale
Perceived Stress Scale (PSS)
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
Baseline5.7 (0 to 40)7.1 (0 to 40)5.8 (0 to 40)
6 hours6.8 (0 to 40)7.2 (0 to 40)4.8 (0 to 40)
7 hours6.3 (0 to 40)7.8 (0 to 40)5.6 (0 to 40)
8 hours5.7 (0 to 40)8.5 (0 to 40)5.2 (0 to 40)
24 hours6.2 (0 to 40)7.8 (0 to 40)6.6 (0 to 40)
SecondaryPatient Rated Inventory of Side Effects (PRISE)

The PRISE is a self-report Adverse Event (AE) Checklist used to qualify side effects by identifying and evaluating the tolerability of each symptom. Only new onset or worsening symptoms were included. Participants could report more than one AE.

Time frame:
24 hours
Reported as:
Count of participants · Participants
Patient Rated Inventory of Side Effects (PRISE)
ParticipantsHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
Decreased energy385
Fatigue493
Dizziness355
Nausea/vomiting055
Dizziness on standing135
Poor concentration233
Headache241
Poor coordination132
Anxiety112
Restlessness211
Palpitations121
Dry mouth211
Sleeping too much021
Tremors030
Blurred vision030
Ringing in ears002
Increased perspiration011
General malaise010
Difficulty sleeping010
Constipation100
SecondaryBrief Psychiatric Rating Scale (BPRS)

The BPRS is a 16-item clinician- administered scale that captures acute behavioral changes throughout treatment. Each item is rated on a scale from 1-7. Full scale from 16-112 with higher score indicating more worse health outcomes.

Time frame:
Baseline, 2, 6, 7, 8, and 24 hours
Reported as:
Mean · score on a scale
Brief Psychiatric Rating Scale (BPRS)
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
Baseline16 (16 to 112)16.1 (16 to 112)16 (16 to 112)
2 hours16 (16 to 112)16.3 (16 to 112)16 (16 to 112)
6 hours16 (16 to 112)16 (16 to 112)16 (16 to 112)
7 hours16 (16 to 112)16 (16 to 112)16 (16 to 112)
8 hours16 (16 to 112)16 (16 to 112)16 (16 to 112)
24 hours16 (16 to 112)16 (16 to 112)16 (16 to 112)
SecondaryColumbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is a clinician-administered suicidal ideation and behavior rating scale used to evaluate suicide risk. Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation).

Time frame:
24 hours
Reported as:
Mean · score on a scale
Columbia Suicide Severity Rating Scale (C-SSRS)
score on a scaleHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
Columbia Suicide Severity Rating Scale (C-SSRS)0 (0 to 9)0 (0 to 9)0 (0 to 9)

Adverse events

Collected over 24 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Harmine Hydrochloride 100mg0/10 (0%)0/10 (0%)2/10 (20%)
Harmine Hydrochloride 200mg0/10 (0%)0/10 (0%)5/10 (50%)
Harmine Hydrochloride >200mg0/5 (0%)0/5 (0%)5/5 (100%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventHarmine Hydrochloride 100mgHarmine Hydrochloride 200mgHarmine Hydrochloride >200mg
Vomiting/emesisGastrointestinal disorders0/103/105/5
Impaired concentration/confusionNervous system disorders1/103/100/5
DrowsinessNervous system disorders0/103/100/5
DizzinessNervous system disorders2/101/101/5
Auditory hallucinationNervous system disorders0/100/101/5
GiddinessNervous system disorders0/100/101/5
HypotensionCardiac disorders0/100/101/5
VasovagalNervous system disorders0/100/101/5
Visual illusionNervous system disorders0/101/100/5
TinglingNervous system disorders0/101/100/5

Baseline characteristics

Harmine 300mg and 500mg combined to maintain confidentiality of one participant in 500mg arm

Age, Continuous
Age, Continuous(years)Harmine Dose 100 mgHarmine 200 mgHarmine >200mgTotal
Median28.9 ± 6.631.1 ± 7.329.4 ± 3.929.9 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)Harmine Dose 100 mgHarmine 200 mgHarmine >200mgTotal
Female55212
Male55313
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Harmine Dose 100 mgHarmine 200 mgHarmine >200mgTotal
Hispanic or Latino3126
Not Hispanic or Latino78318
Unknown or Not Reported0101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Harmine Dose 100 mgHarmine 200 mgHarmine >200mgTotal
American Indian or Alaska Native1001
Asian2507
Native Hawaiian or Other Pacific Islander0000
Black or African American2013
White45312
More than one race1012
Unknown or Not Reported0000
Weight
Weight(kg)Harmine Dose 100 mgHarmine 200 mgHarmine >200mgTotal
Mean66.2 ± 10.869.7 ± 14.976 ± 22.669.6 ± 15
Body mass index
Body mass index(kg/m^2)Harmine Dose 100 mgHarmine 200 mgHarmine >200mgTotal
Mean24.8 ± 2.724.5 ± 3.025.2 ± 4.024.8 ± 3.0
Education level
Education level(Participants)Harmine Dose 100 mgHarmine 200 mgHarmine >200mgTotal
Some college1001
Graduated 2-year college/trade school0101
Graduated 4-year college2024
Some graduate/professional school34310
Completed graduate/professional school4509
Marital status
Marital status(Participants)Harmine Dose 100 mgHarmine 200 mgHarmine >200mgTotal
Married/living with someone as if married4419
Never married66416
08

Study locations

1 site
  • Depression and Anxiety Center
    New York, New York 10029, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — As of now the study team is not plan on sharing IPD as that would not align with the approved management plan.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jun 2023, 9 months.

Results were first posted in Jan 2025, 1 year 6 months after primary completion.

Of 76 non-industry phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 55. This study's 9 months is below that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2022
First posted
Sep 2, 2022
StartActual
Sep 13, 2022
Primary completionActual
Jun 23, 2023
CompletionActual
Jun 23, 2023
Results first posted
Jan 16, 2025
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05526430
Lead sponsor
James Murrough
Responsible party
James Murrough (Associate Professor, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Sep 2, 2022
Start date
Sep 13, 2022
Primary completion
Jun 23, 2023
Completion
Jun 23, 2023
Results posted
Jan 16, 2025
Last update
Jan 16, 2025

Study contacts

James Murrough, MD, PhD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion